PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation is a research paper published in Frontiers in Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 34 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIBIB NIH HHS
Grant: P41 EB024495
NCI NIH HHS
Grant: R01 CA253617
National Institutes of Health
Grant: R01 CA253617, P30 CA006973, P41 EB024495, R01 CA82337, R35 CA209960
NCI NIH HHS
Grant: P30 CA006973
NCI NIH HHS
Grant: R01 CA082337
NCI NIH HHS
Grant: R35 CA209960
National Institutes of Health
Grant: 3P30CA006973-53S2
Regional Oncology Research Center
National Institutes of Health
Grant: 5P41EB024495-02
Resource for Molecular Imaging Agents in Precision Medicine
National Institutes of Health
Grant: 1R01CA082337-01
HOSTILE ENVIRONMENTS PROMOTE INVASION AND METASTASIS
National Institutes of Health
Grant: 1R01CA253617-01
The Tumor Microenvironment in Nanoparticle Delivery and Function
European Commission
Grant: 795272
Advanced Theranostic Nanomedicines for Oncology. Development of new combinatorial therapies for primary and metastatic Breast Cancer.
National Institutes of Health
Grant: 5R35CA209960-07
Molecular Imaging and Theranostics of Cancer
Fundación Alfonso Martín Escudero
H2020 Marie Skłodowska-Curie Actions
FWCI
1.53
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals